Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study - Concepedia

Concepedia

Publication | Open Access

Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study

DOI Full Paper Access

69

Citations

30

References

2021

Year

Rosario Pivonello, Irina Bancos, Richard A. Feelders, Atil Y. Kargi, Janice M. Kerr, Murray B. Gordon, Cary N. Mariash, Massimo Terzolo, Noel Ellison, Andreas Moraitis

Frontiers in Endocrinology

Abstract

The SGRM relacorilant provided clinical benefit to patients with CS without undesirable antiprogesterone effects or drug-induced hypokalemia.

References

	Year	Citations

Page 1